Ardelyx, Inc. (ARDX) Stock Price & Analysis

Ardelyx, Inc. (ARDX) is trading at USD 3.09, down 0.48% today, as of October 29, 2026 at 18:20 UTC (US market open; quotes may be delayed), according to Nexqual market data.

ARDX last closed at USD 3.1; today's session has ranged USD 3.08–3.16 on volume of 1,142,421 shares. Market capitalization is $796.51M, with a 52-week range of USD 2.96–8.4 (NGM). Source: Nexqual, retrieved October 29, 2026 at 18:20 UTC.

Also available as compact Markdown for AI agents: nexqual.com/ARDX.md

Key facts (ARDX)

• Last four reported quarters (through Jun 30, 2026): revenue $451M, net income -$55.7M (-12.4% margin), free cash flow -$17.9M (SEC filings).
• Insider open-market sales, last ~7 months: 21 Form 4 filings, $2.5M; 16 not under a Rule 10b5-1 plan ($1.0M); 0 by opportunistic insiders, 9 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 1.91 on a 1–5 scale) (11 analysts), mean target USD 12.8 (range 8–18).
• Total return with dividends: 1Y -37.8% vs S&P 500 +12.8%; 5Y +155.0% vs S&P 500 +78.7%.
• Next earnings: 2026-11-03, EPS estimate USD -0.02, revenue estimate $129M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ARDX)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (ARDX)

P/S 1.8x · EV/Sales 1.7x · P/B 5.3x · FCF yield -2.25% · Earnings yield -6.99% · Net cash $30.0M · EV $767M

Insider sales (SEC Form 4, open-market, last ~7 months) (ARDX)

5 of 21 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (ARDX)

Consensus Buy (mean 1.91 on a 1–5 scale), 11 analysts; mean target USD 12.8 (low 8, high 18).

Rating changes, last 120 days:

Total return (dividends reinvested) (ARDX)

ARDX earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

ARDX recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

ARDX suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 19, 2026.

Companies that name ARDX in their SEC reports

ARDX analyst estimates and revisions

Key Statistics (as of October 29, 2026 at 18:20 UTC)

Technical Analysis (ARDX)

Nexqual's technical model rates ARDX "STRONG SELL" based on 0 bullish and 5 bearish signals across 128 daily candles, as of October 29, 2026 at 18:20 UTC.

Analyst Ratings (ARDX)

Wall Street analysts rate ARDX "Buy" based on 11 analysts, with a mean price target of USD 12.8 (range USD 8–18), per Nexqual as of October 29, 2026 at 18:20 UTC.

Earnings (ARDX)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 18:20 UTC.

Financials & Fundamentals (ARDX)

Source: Nexqual, October 29, 2026 at 18:20 UTC.

Financial Health Score (ARDX)

Nexqual rates Ardelyx, Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 18:20 UTC.

Ownership (ARDX)

Source: Nexqual, October 29, 2026 at 18:20 UTC.

Leadership (ARDX)

Ardelyx, Inc. is led by Michael G. Raab, President, CEO & Director, per Nexqual as of October 29, 2026 at 18:20 UTC.

Major Backers & Investors (ARDX)

Notable institutional backers of Ardelyx, Inc. include Rubric Capital Management LP, Millennium Management, Nomura Asset Management International Inc, according to Nexqual as of October 29, 2026 at 18:20 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 18:20 UTC.

From Ardelyx, Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)

Key Strengths & Strategy (as disclosed to the SEC)

• Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology.
• After the FDA evaluates the NDA and conducts inspections of manufacturing facilities where the drug product and/or its API will be produced, if deemed necessary, it may issue an approval letter or a Complete Response Letter.
• Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our products, drug candidates, manufacturing and process discoveries and other know-how, to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights.
• We also rely on trade secrets and careful monitoring of our proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.

Partnerships

• We have an exclusive license agreement with Knight for the development, commercialization and distribution of tenapanor in Canada for hyperphosphatemia and IBS-C.
• We have an exclusive license agreement with Kyowa Kirin for the development, commercialization and distribution of tenapanor in Japan for cardiorenal indications.

Legal & Regulatory Risks (Item 1A, quoted)

• The One Big Beautiful Bill Act, which was enacted in July 2025, imposes significant reductions in the funding of the Medicaid program. Such reductions are expected to decrease the number of persons enrolled in Medicaid and reduce the services covered by Medicaid, which could adversely affect our sales of our partner's products or of any product candidate that we commercialize.
• We cannot predict the reform initiatives that may be adopted in the future or whether initiatives that have been adopted will be repealed or modified.
• Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity.
• We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the U.S. or abroad.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 18:20 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt